Endocrine Abstracts

Promotion of brown adipose tissue (BAT) activity or browning of white adipose tissue has shown great potential as anti-obesity strategy in numerous preclinical models. The discovery of active BAT in humans and the recent advances in the understanding of human BAT biology and function have sparked this field of research. Pharmacological stimulation of energy expenditure to counteract obesity has always been an intriguing therapeutic concept; the identification of the specific m...

see P728....

The serum- and glucocorticoid-regulated kinase 1 (Sgk1) is a direct transcriptional target of glucocorticoids and is post-translationally activated by the insulin/IGF1 pathway. Distinct polymorphisms in the Sgk1 gene are associated with increased body weight and type 2 diabetes. Here we investigate the expression and regulation of Sgk1 in human obesity.In both omental and subcutaneous human adipose tissue, Sgk1 expression is significantly increased in 20...

Serum and glucocorticoid-induced kinase 1 (Sgk1) is an early transcriptional target of glucocorticoids with antiapoptotic effects. Sgk1 becomes active after phosphorylation by growth factors such as insulin and IGF1 through the PI3 kinase/PDK1 pathway. Activated Sgk1 increases the cellular uptake of glucose by increasing the membrane abundance of glucose transporters GLUT1 and GLUT4. Here we present data on the expression and regulation of Sgk1 in adipose tissue using three di...

Objectives: To describe the baseline characteristics of individuals enrolled in CAHtalyst (NCT04490915), a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the safety and efficacy of crinecerfont (a corticotropin-releasing factor type 1 receptor [CRF1] antagonist) in adults with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD).Methods: The study included adults (age ≥18 years) with cl...

Introduction: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), a genetic condition characterized by cortisol deficiency and excess adrenal androgens, typically requires management with supraphysiological glucocorticoid (GC) doses. This multinational Phase 3 study (CAHtalyst™) evaluated whether crinecerfont, an oral CRF1 antagonist, can reduce GC dose while maintaining androgen control in adults with CAH.Metho...

BackgroundPrenatal dexamethasone treatment (Pdex) has been used since the 1980s to prevent virilization in female offspring suspected to have congenital adrenal hyperplasia (CAH). However, due to lack of strong evidence for its best practice as well as limited data regarding longterm adverse effects, use of dex is highly controversial. This study reveals the current medical practice regarding Pdex in female fetuses at risk of CAH due to 21hydroxylase def...